01 December 2017
: Case report
Encephalocraniocutaneous Lipomatosis: Haberland Syndrome
Rare disease
Selçuk Özdoğan1ABCDEF*, Ceyhun Saymaz2BCD, Cumhur Kaan Yaltırık3AE, Hanife Gülden Düzkalır4CD, Mustafa Kaya5DF, Nail Demirel1AB, Ali Haluk Düzkalır6EF, Başar Sarıkaya7BC, Berrin Aktekin8ADEDOI: 10.12659/AJCR.907685
Am J Case Rep 2017; 18:1271-1275
Abstract
BACKGROUND: Encephalocraniocutaneous lipomatosis (ECCL) was first announced as a new type of ectomesodermal dysgenesis in 1970 by Haberland and Perou. ECCL was first described in 1970, and approximately 60 cases have been reported since then. The classic triad of ECCL are skin, ocular, and central nervous system involvement, including conditions such as unilateral porencephalic cyst, ipsilateral lipomatous hamartoma of the scalp-eyelids-eye globe, cortical atrophy, cranial asymmetry, developmental delay, seizures, mental retardation, and spasticity of the contralateral limbs. The dermatological hallmark is a hairless fatty tissue nevus of the scalp called nevus psiloliparus.
CASE REPORT: An 11-year-old right-handed boy, born at full term, was referred to our clinic. His family had no consanguinity or history of neurocutaneous disease. The patient’s physical examination revealed a large hairless lesion on the right frontoparietal scalp called nevus psiloliparus. Beginning from the birth, a dermolipoma (an uncommon benign tumor) was reported to have occurred on the conjunctiva, mostly ipsilateral in his right eye and present on the ipsilateral side of the neurological abnormalities shown on magnetic resonance imaging and computed tomography. The patient had muscle weakness in left upper and lower extremities. He had a mild form of mental retardation.
CONCLUSIONS: There is no specific treatment for ECCL. Management of ECCL is usually symptomatic. Surgical correction of a cutaneous lesion can be performed for cosmetic improvement. An early diagnosis of ECCL allows for early symptom treatment and improved patient quality of life.
Keywords: Epilepsy, Absence, Lipoma, Neurocutaneous Syndromes
1434 8
Editorial
01 October 2023 : Editorial
Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air PollutionDOI: 10.12659/MSM.942672
Med Sci Monit 2023; 29:e942672
In Press
04 Oct 2023 : Clinical Research
A Retrospective Study of 205 Patients with Complex Kidney Stones to Compare Outcomes from Super-Mini Percut...Med Sci Monit In Press; DOI: 10.12659/MSM.941012
03 Oct 2023 : Clinical Research
Prevalence and Risk Factors for Modic Changes in Symptomatic Cervical Ossification of the Posterior Longitu...Med Sci Monit In Press; DOI: 10.12659/MSM.941674
03 Oct 2023 : Clinical Research
Time-Dependent Factors Influencing Cardiocerebral Vascular Events in Chronic Hemodialysis Patients: Insight...Med Sci Monit In Press; DOI: 10.12659/MSM.941553
02 Oct 2023 : Clinical Research
Comparison of Nanocrystalline Hydroxyapatite Bone Graft with Empty Defects in Long Bone Fractures: A Retros...Med Sci Monit In Press; DOI: 10.12659/MSM.941112
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292